Celgene’s Busy Week

It wasn’t until the final week in April that Celgene Corporation (NASDAQ: CELG) took the title of top deal maker for the month. The single acquisition on the books as of April 24 was its collaboration with MedImmune (NYSE: AZN) on its anti-PD-L1 inhibitor MEDI4736, with $450 million in cash upfront. On April 27, CELG […]